Muscaritoli M, Conversano L, Torelli G F, Arcese W, Capria S, Cangiano C, Falcone C, Rossi Fanelli F
Department of Clinical Medicine, University La Sapienza, Rome, Italy.
Transplantation. 1998 Sep 15;66(5):610-6. doi: 10.1097/00007890-199809150-00011.
Nutrients may interfere with physiological and pathophysiologic mechanisms. The present study was aimed at evaluating whether the differences in the quality of energy substrates administered with total parenteral nutrition (TPN) after cytoreductive therapy may influence the clinical outcome of patients undergoing bone marrow transplantation (BMT).
Sixty-six consecutive allogeneic BMT patients with hematologic malignancies were randomized to receive either a glucose-based (100% glucose) or a lipid-based (80% lipid, using an omega-6 long-chain triacylglycerol emulsion + 20% glucose) TPN, providing 146.3 kJ/kg body weight, 1.4 g of protein/kg of body weight, administered from day +1 to day +15 after BMT. Time to engraftment (EGT), incidence of sepsis and metabolic complications (hyperglycemia and hypertriglyceridemia), incidence of acute graft-versus-host-disease (A-GVHD) and relapse, survival at 18 months, incidence of deaths for A-GVHD and relapse were evaluated.
Six patients dropped out before completing the study period. Thirty-one patients in the glucose-based TPN group and 29 patients in the lipid-based TPN group were evaluated. The incidence of hyperglycemia was significantly lower in the lipid-based TPN group than in the glucose-based TPN group (3.4% vs. 32%, respectively; P=0.004). Five patients in the glucose group and none in the lipid group died for A-GVHD (P<0.05). Survival at 18 months tended to be higher in the lipid group than in the glucose group (62% vs. 42%, P=NS). Rate of bone-marrow EGT, time to EGT, incidence of sepsis and fungal infections during TPN, incidence of A-GVHD, and rate of relapse at 18 months were not different in the two groups.
The results obtained suggest that the use of lipid-based TPN after allogeneic BMT is associated with lower incidence of lethal A-GVHD and hyperglycemia, without negatively affecting the EGT of infused cells. Intravenously administered lipids might have influenced the severity of A-GVHD likely via modulation of immune response and synthesis of cytokines, prostaglandins, and leukotrienes that participate in the pathogenesis of graft-versus-host disease.
营养物质可能会干扰生理和病理生理机制。本研究旨在评估减瘤治疗后全胃肠外营养(TPN)所给予的能量底物质量差异是否会影响接受骨髓移植(BMT)患者的临床结局。
66例连续的血液系统恶性肿瘤异基因BMT患者被随机分为接受基于葡萄糖的(100%葡萄糖)或基于脂质的(80%脂质,使用ω-6长链三酰甘油乳剂+20%葡萄糖)TPN,提供146.3kJ/kg体重、1.4g蛋白质/kg体重,于BMT后第+1天至第+15天给予。评估植入时间(EGT)、败血症和代谢并发症(高血糖和高甘油三酯血症)的发生率、急性移植物抗宿主病(A-GVHD)和复发的发生率、18个月时的生存率、A-GVHD和复发导致的死亡发生率。
6例患者在完成研究期前退出。对基于葡萄糖的TPN组的31例患者和基于脂质的TPN组的29例患者进行了评估。基于脂质的TPN组高血糖的发生率显著低于基于葡萄糖的TPN组(分别为3.4%和32%;P=0.004)。葡萄糖组有5例患者死于A-GVHD,脂质组无患者死于A-GVHD(P<0.05)。脂质组18个月时的生存率倾向于高于葡萄糖组(62%对42%,P=无显著性差异)。两组的骨髓EGT率、EGT时间、TPN期间败血症和真菌感染的发生率、A-GVHD的发生率以及18个月时的复发率无差异。
所获得的结果表明,异基因BMT后使用基于脂质的TPN与致死性A-GVHD和高血糖的发生率较低相关,且不会对输注细胞的EGT产生负面影响。静脉输注脂质可能通过调节参与移植物抗宿主病发病机制的免疫反应以及细胞因子、前列腺素和白三烯的合成,影响了A-GVHD的严重程度。